184 related articles for article (PubMed ID: 35932175)
1. Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors.
Gibiansky L; Passey C; Voellinger J; Gunawan R; Hanley WD; Gupta M; Winter H
CPT Pharmacometrics Syst Pharmacol; 2022 Oct; 11(10):1358-1370. PubMed ID: 35932175
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies.
Li H; Han TH; Hunder NN; Jang G; Zhao B
J Clin Pharmacol; 2017 Sep; 57(9):1148-1158. PubMed ID: 28513851
[TBL] [Abstract][Full Text] [Related]
3. Tisotumab Vedotin: First Approval.
Markham A
Drugs; 2021 Dec; 81(18):2141-2147. PubMed ID: 34748188
[TBL] [Abstract][Full Text] [Related]
4. Tisotumab vedotin for the treatment of cervical carcinoma.
Song X; Li R; Wang H; Song P; Guo W; Chen ZS
Drugs Today (Barc); 2022 May; 58(5):213-222. PubMed ID: 35535813
[TBL] [Abstract][Full Text] [Related]
5. Exposure-safety and exposure-efficacy analyses for tisotumab vedotin for patients with locally advanced or metastatic solid tumors.
Passey C; Voellinger J; Gibiansky L; Gunawan R; Nicacio L; Soumaoro I; Hanley WD; Winter H; Gupta M
CPT Pharmacometrics Syst Pharmacol; 2023 Sep; 12(9):1262-1273. PubMed ID: 37496366
[TBL] [Abstract][Full Text] [Related]
6. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
de Bono JS; Concin N; Hong DS; Thistlethwaite FC; Machiels JP; Arkenau HT; Plummer R; Jones RH; Nielsen D; Windfeld K; Ghatta S; Slomovitz BM; Spicer JF; Yachnin J; Ang JE; Mau-Sørensen PM; Forster MD; Collins D; Dean E; Rangwala RA; Lassen U
Lancet Oncol; 2019 Mar; 20(3):383-393. PubMed ID: 30745090
[TBL] [Abstract][Full Text] [Related]
7. A review of the novel tissue factor antibody-drug conjugate: Tisotumab vedotin.
Luu K; Chu A; Chang B
J Oncol Pharm Pract; 2023 Mar; 29(2):441-449. PubMed ID: 36415085
[TBL] [Abstract][Full Text] [Related]
8. Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.
Kågedal M; Gibiansky L; Xu J; Wang X; Samineni D; Chen SC; Lu D; Agarwal P; Wang B; Saad O; Koppada N; Fine BM; Jin JY; Girish S; Li C
J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):537-548. PubMed ID: 28918591
[TBL] [Abstract][Full Text] [Related]
9. A Review of Tisotumab Vedotin-tftv in Recurrent or Metastatic Cervical Cancer.
Heitz N; Greer SC; Halford Z
Ann Pharmacother; 2023 May; 57(5):585-596. PubMed ID: 35962528
[TBL] [Abstract][Full Text] [Related]
10. Clinical Pharmacology of the Antibody-Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors.
Tang M; Garg A; Bonate PL; Rosenberg JE; Matsangou M; Kadokura T; Yamada A; Choules M; Pavese J; Nagata M; Tenmizu D; Koibuchi A; Heo N; Wang L; Wojtkowski T; Hanley WD; Poondru S
Clin Pharmacokinet; 2024 Apr; 63(4):423-438. PubMed ID: 38609704
[TBL] [Abstract][Full Text] [Related]
11. Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody-drug conjugates.
Chen Y; Samineni D; Mukadam S; Wong H; Shen BQ; Lu D; Girish S; Hop C; Jin JY; Li C
Clin Pharmacokinet; 2015 Jan; 54(1):81-93. PubMed ID: 25223698
[TBL] [Abstract][Full Text] [Related]
12. SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models.
Gray E; Ulrich M; Epp A; Younan P; Sahetya D; Hensley K; Allred S; Huang LY; Hahn J; Gahnberg K; Treuting PM; Trueblood ES; Gosink JJ; Thurman R; Wo S; Spahr K; Haass EJ; Snead K; Miller D; Padilla M; Smith AJ; Frantz C; Schrum JP; Nazarenko N; Gardai SJ
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37793853
[TBL] [Abstract][Full Text] [Related]
13. Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment.
Zhao B; Chen R; O'Connor OA; Gopal AK; Ramchandren R; Goy A; Matous JV; Fasanmade AA; Manley TJ; Han TH
Br J Clin Pharmacol; 2016 Sep; 82(3):696-705. PubMed ID: 27115790
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Characterization of the Distribution, Catabolism, and Elimination of a Polatuzumab Vedotin-Piiq (POLIVY
Yip V; Lee MV; Saad OM; Ma S; Khojasteh SC; Shen BQ
J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33806916
[TBL] [Abstract][Full Text] [Related]
15. Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody-Drug Conjugate in Mice.
Chang HP; Li Z; Shah DK
Pharm Res; 2022 Jan; 39(1):1-24. PubMed ID: 35044590
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
Coleman RL; Lorusso D; Gennigens C; González-Martín A; Randall L; Cibula D; Lund B; Woelber L; Pignata S; Forget F; Redondo A; Vindeløv SD; Chen M; Harris JR; Smith M; Nicacio LV; Teng MSL; Laenen A; Rangwala R; Manso L; Mirza M; Monk BJ; Vergote I;
Lancet Oncol; 2021 May; 22(5):609-619. PubMed ID: 33845034
[TBL] [Abstract][Full Text] [Related]
17. Tisotumab vedotin in recurrent or metastatic cervical cancer.
Bogani G; Coleman RL; Vergote I; Raspagliesi F; Lorusso D; Monk BJ
Curr Probl Cancer; 2023 Jun; 47(3):100952. PubMed ID: 36842202
[TBL] [Abstract][Full Text] [Related]
18. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies.
Hu XY; Wang R; Jin J; Liu XJ; Cui AL; Sun LQ; Li YP; Li Y; Wang YC; Zhen YS; Miao QF; Li ZR
Mol Oncol; 2019 Feb; 13(2):246-263. PubMed ID: 30372581
[TBL] [Abstract][Full Text] [Related]
19. Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non-Hodgkin Lymphoma.
Lu D; Lu T; Gibiansky L; Li X; Li C; Agarwal P; Shemesh CS; Shi R; Dere RC; Hirata J; Miles D; Chanu P; Girish S; Jin JY
CPT Pharmacometrics Syst Pharmacol; 2020 Jan; 9(1):48-59. PubMed ID: 31749251
[TBL] [Abstract][Full Text] [Related]
20. CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies.
Han TH; Gopal AK; Ramchandren R; Goy A; Chen R; Matous JV; Cooper M; Grove LE; Alley SC; Lynch CM; O'Connor OA
J Clin Pharmacol; 2013 Aug; 53(8):866-77. PubMed ID: 23754575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
